Maxion Therapeutics
UK - CambridgeBiotechnology
Focus: Maxion Therapeutics is a UK-based biotech company specializing in miniproteins engineered into antibody loops, a novel modality platform approach. The company is publicly listed and operates at an early-stage discovery/development phase with minimal commercial infrastructure.
Profile data last refreshed 8h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
1-1 this month
Stable — net -1 jobs in 30d
1 added, 2 removed. Backfill posture.
Should You Work at Maxion Therapeutics?
AI assessmentBest suited for early-career or risk-tolerant scientists seeking deep technical work on a novel platform; poor fit for those prioritizing job security, salary transparency, or clear clinical milestones.
Why Work Here
- Early-stage platform play with defensible IP in miniprotein-antibody conjugates, offering scientists ground-floor exposure to novel modality development.
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Open Jobs (1)
Interview Prep Quick Facts
Help build intelligence for Maxion Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.